Metastatic sarcoma: tailored strategies for a heterogeneous disease

Massimiliano Grassi, Andrea Spagnoletti, Alberto Puccini

Research output: Contribution to journalReview article


Soft tissue sarcomas are rare diseases that encompass a very heterogeneous group of tumors with diverse pathology and clinically overlapping characteristics. Although some treatment options may be used across different subtypes, each is characterized by specific features and may benefit more from specific approaches. In such a rare and peculiar group of diseases, it is rather important to define the best strategy to prolong survival and improve the quality of life of the patients. Although anthracycline-based chemotherapy remains a milestone in the first-line setting, in recent years novel targeted and immune therapies have been developed and more tailored strategies are possible. For these reasons, every case should be discussed in a multidisciplinary board that includes all specialists involved in the treatment of these patients, since the combination of systemic and local treatments can often be proposed. In this short review, we present the state of the art and offer future perspectives for the management of soft tissue sarcomas.

Original languageEnglish
JournalMemo - Magazine of European Medical Oncology
Publication statusAccepted/In press - Jan 1 2020


  • Chemotherapy
  • Palliative care
  • Precision medicine
  • Soft tissue sarcoma
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Metastatic sarcoma: tailored strategies for a heterogeneous disease'. Together they form a unique fingerprint.

  • Cite this